Corina Bocşan 1, V. Cristea 2
1 Department of Clinical Pharmacology, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
2 Department of Immunopathology, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Abstract
Allergic rhinitis is an immune inflammatory process, IgE mediated, which affects nasal mucosa. The immune allergic response presents 3 phases and involves many cells and mediators. Interleukins are involved both in producing and maintaining this process. Il-1, Il-6 and TNF-a increase allergic inflammation and are involved in producing the late phase of inflammation. The studies regarding unique or continuous exposure to specific allergens of the patients with allergic rhinitis revealed the increase of the proinflammatory cytokines level both in nasal secretion and in plasma. Histamine is the main mediator involved in allergic rhinitis through type 1 specific receptors. H1 antihistamines are first line treatment in all forms of allergic rhinitis. New generation antihistamines possess some anti-inflammatory properties, especially relevant in vitro studies and sometimes in vivo studies. Keywords: H1 antihistamines, anti-inflammatory effect, interleukines